my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Company Portrait
Galapagos is a drug discovery company with pre-clinical programs in bone and joint diseases and cachexia. Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as chemogenomics and ADMET database products to select targets and compounds. Galapagos currently employs 460 people and operates facilities in seven countries, with global headquarters in Mechelen, Belgium.
Industrial Sectors
Contact / Request information
Contact the company and request further information free of charge:
Watchlist
This is where you can add this company to your personal favourites
Galapagos acquires Cangenix, a structure-based drug discovery company
Galapagos NV (GLPG) and Cangenix Ltd announced that Galapagos has acquired Cangenix to add structure-based drug discovery to the Argenta service offering. Under the terms of the acquisition agreement, Galapagos will pay a total cash consideration of £1 million, with a further £440,000 pot ... more
Galapagos discovers novel class of antibiotics
Galapagos NV announced that it has discovered an entirely new class of antibiotics. The Company has selected a candidate drug that shows strong activity against all tested drug resistant Staphylococcus aureus, including hospital and community acquired MRSA strains.Bacterial infections that ... more
Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders
Galapagos NV announced that its service division BioFocus and Ono Pharmaceutical Co., Ltd. have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders. Under the new agreement, BioFocus will use its drug discovery platform to deliver leads an ... more
Galapagos is a drug discovery company with pre-clinical programs in bone and joint diseases and cachexia. Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery an ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Companies
Netmeeting
